BiomX - contemplated consideration for 60% of TSOOCK is $10.4 mln

BiomX Inc. (NYSE American: PHGE) has announced its contemplation of a transaction involving TSOOCK, with an estimated consideration of $10.4 million for 60% of the company. This potential deal aligns with BiomX’s ongoing strategy to expand its portfolio of innovative therapies and technologies. The company has demonstrated a history of strategic acquisitions and partnerships, including its recent DFSL’s LADAR-based detection systems integration into its defense portfolio.

The proposed consideration for TSOOCK reflects BiomX’s focus on allocating capital to opportunities that align with its long-term objectives. The company has previously raised significant capital through private placements, including a $50 million Adaptive Phage financing. These funds have been directed toward advancing clinical programs such as BX004 for cystic fibrosis and BX211 for diabetic foot osteomyelitis, with key data readouts expected in 2025.

BiomX’s financial position remains a subject of scrutiny, as its recent financial statements include an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern, primarily due to uncertainties surrounding the conversion of convertible preferred stock. However, the company has secured sufficient funding for operations and clinical milestones for the next two years.

The potential acquisition of TSOOCK would represent another step in BiomX’s broader strategy to diversify its offerings and strengthen its market position. As with previous transactions, the success of this contemplated deal will depend on regulatory approvals, strategic alignment, and the ability to integrate new capabilities effectively. Investors will be watching closely for updates on the progress of this initiative and its impact on BiomX’s financial and operational outlook.